☆Foresite Capital Management VI LLC
Quality Q
0.507
AUM ($M)
643
Positions
23
Turnover
0.26
Top-10 wt
82%
Herfindahl
0.124
History (qtrs)
6
Excess Return
—
AI Eval Run AI Eval
Holdings · 25 positions · portfolio value $643M
| Ticker | Name | Activity | Security Type | Weight | Δ Weight | Value ($M) | Shares | Δ Shares | Qtrs Held | Excess Return |
|---|---|---|---|---|---|---|---|---|---|---|
| ☆CGON funds › | CG Oncology, Inc. | ADD | — | 26.2% | -6.5% | 168.4 | 2,369,574 | +148,100 | 5 | — |
| ☆ALMS funds › | ALUMIS INC. | HOLD | — | 18.6% | -1.7% | 119.5 | 4,247,670 | +0 | 5 | — |
| ☆SPTX funds › | Seaport Therapeutics, Inc. | NEW | — | 6.0% | +6.0% | 38.7 | 1,779,521 | +1,779,521 | 1 | — |
| ☆DNLI funds › | Denali Therapeutics Inc. | ADD | — | 5.6% | +0.5% | 35.9 | 1,396,771 | +186,800 | 4 | — |
| ☆CLDX funds › | Celldex Therapeutics, Inc. | ADD | — | 5.1% | +2.9% | 32.7 | 879,713 | +563,800 | 2 | — |
| ☆AGIO funds › | AGIOS PHARMACEUTICALS, INC. | ADD | — | 4.5% | +0.7% | 29.1 | 785,000 | +260,000 | 3 | — |
| ☆CRVS funds › | Corvus Pharmaceuticals, Inc. | HOLD | — | 4.3% | -1.6% | 27.4 | 1,831,233 | +0 | 5 | — |
| ☆PBLS funds › | Parabilis Medicines, Inc. | NEW | — | 4.3% | +4.3% | 27.3 | 999,044 | +999,044 | 1 | — |
| ☆GHRS funds › | GH Research PLC | ADD | — | 3.9% | +3.0% | 25.3 | 940,493 | +625,001 | 2 | — |
| ☆JBIO funds › | Jade Biosciences, Inc. | ADD | — | 3.1% | +2.1% | 19.7 | 886,667 | +566,667 | 2 | — |
| ☆HNGE funds › | Hinge Health, Inc. | HOLD | — | 2.8% | +1.0% | 18.3 | 220,400 | +0 | 5 | — |
| ☆KYMR funds › | Kymera Therapeutics, Inc. | HOLD | — | 2.6% | -0.0% | 16.8 | 146,332 | +0 | 5 | — |
| ☆ATAI funds › | AtaiBeckley Inc. | HOLD | — | 2.3% | +0.1% | 14.5 | 2,750,000 | +0 | 2 | — |
| ☆VSTM funds › | Verastem, Inc. | HOLD | — | 1.9% | -1.8% | 12.0 | 3,146,631 | +0 | 5 | — |
| ☆BEAM funds › | Beam Therapeutics Inc. | NEW | — | 1.8% | +1.8% | 11.3 | 330,000 | +330,000 | 1 | — |
| ☆NERV funds › | Minerva Neurosciences, Inc. | TRIM | — | 1.7% | -0.9% | 11.0 | 1,985,584 | -1,016 | 2 | — |
| ☆AVBP funds › | ArriVent BioPharma, Inc. | NEW | — | 1.6% | +1.6% | 10.5 | 301,341 | +301,341 | 1 | — |
| ☆AURA funds › | Aura Biosciences, Inc. | NEW | — | 1.5% | +1.5% | 9.5 | 1,333,334 | +1,333,334 | 1 | — |
| ☆CRNX funds › | Crinetics Pharmaceuticals, Inc. | HOLD | — | 1.2% | -0.4% | 7.9 | 212,010 | +0 | 2 | — |
| ☆RACC funds › | Research Alliance Corp III | NEW | — | 0.5% | +0.5% | 3.2 | 300,000 | +300,000 | 1 | — |
| ☆ZURA funds › | Zura Bio Ltd | HOLD | — | 0.4% | -0.2% | 2.7 | 450,000 | +0 | 2 | — |
| ☆KLRA funds › | Kailera Therapeutics, Inc. | NEW | — | 0.1% | +0.1% | 0.8 | 37,500 | +37,500 | 1 | — |
| ☆IRON funds › | Disc Medicine, Inc. | NEW | — | 0.0% | +0.0% | 0.1 | 970 | +970 | 1 | — |
| ☆CUSIP:152309100 funds › | Centessa Pharmaceuticals plc | EXIT | — | 0.0% | -11.8% | 0.0 | 0 | -1,364,019 | 0 | — |
| ☆OKUR funds › | OnKure Therapeutics, Inc. | EXIT | — | 0.0% | -1.3% | 0.0 | 0 | -1,445,783 | 0 | — |
Point-in-time history
| Period | AUM ($M) | Positions | Turnover | Top-10 wt | Herfindahl | Quality Q | Skill | Universe |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 643 | 23 | 0.26 | 82% | 0.124 | 0.506 | — | in |
| 2026Q1 | 460 | 17 | 0.29 | 91% | 0.174 | 0.505 | — | in |
| 2025Q4 | 331 | 12 | 0.19 | 95% | 0.145 | 0.644 | — | in |
| 2025Q3 | 259 | 12 | 0.26 | 99% | 0.180 | 0.499 | — | in |
| 2025Q2 | 178 | 20 | 0.25 | 84% | 0.142 | 0.363 | — | entered |
| 2025Q1 | 183 | 14 | 0.00 | 94% | 0.146 | 0.000 | — | out |
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short.
JSON: /api/signals ·
/api/funds ·
/api/status